Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine 1000 mg TID vs 2x500 mg TID in Active Ulcerative Colitis
NCT01745770Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Salcrozine in ulcerative colitis (UC), sponsored by Dr. Falk Pharma GmbH. Started Jan 2013; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01745770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01745770.